DiObex, Inc. Awarded Patent for the Prevention of Insulin-Induced Hypoglycemia

...poglycemia in diabetes patients. The patent grants diobex exclusive rights to methods of reducing the risk o...s. In addition to the recently issued U.S. patent, diobex owns seven U.S. patent applications and 30 corresp...g foreign patent applications relating to DIO-901. diobex also owns or has exclusively licensed seven U.S. p...

DiObex Begins Dosing Patients in Phase 2b Trial of Type 2 Diabetes Drug

...ditional indications under evaluation for DIO-902, diobex is well positioned to move a strong pipeline of pr...d more effective than racemic ketoconazole. About diobex DiObex, Inc. is a San Francisco-based biotechnolo... products for the treatment of metabolic diseases. diobex has two product candidates in Phase 2 clinical dev...

Diobex Announces Successful Completion of Phase 2a Trial Of DIO-902, a Novel Cortisol Synthesis Inhibitor for Type 2 Diabetes

...citing new drug category," commented Daniel Green, diobex President. "DIO-902 offers the possibility of ad..., M.D., Vice President of Development at DiObex. diobex plans on initiating a 16-week phase 2b dose-ranging study with DIO- 902 in mid 2007. About diobex DiObex, Inc. is a San Francisco-based biopharmac...

DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein

...ations normalized during the two week treatment. diobex will conduct a multi-center, 16-week, phase 2b dos...g patients in three countries in mid-2007. About diobex DiObex, Inc. is a San Francisco-based biopharmac... products for the treatment of metabolic diseases. diobex has two products preparing to enter Phase 2b clini...

DiObex in Biological Technology

DiObex Announces Presentation of Scientific Poster at Annual Meeting of American Society for Clinical Pharmacology and Therapeutics

...2 is an oral, single enantiomer of ketoconazole, a common anti-fungal drug. diobex is developing DIO-902 as a novel cortisol inhibitor for treating type 2 dia...logy company developing novel products for diabetes and metabolic diseases. diobex has two product candidates in four mid-stage clinical development programs....

DiObex and Camurus Sign License Agreement for the Development of DIO-901 in FluidCrystal(R) Extended Release Technology

...ANCISCO and LUND, Sweden, March 18 /PRNewswire/ -- diobex and Camurus announced today that they have signed ...ality of life to coma and death," said David Cory, diobex CEO. "This license agreement and development progr...in-induced hypoglycemia in patients with diabetes. diobex has successfully completed three Phase 1 proof-of-...

DiObex, Inc. to Present at Merrill Lynch Global Healthcare Conference

...te presentation at the upcoming Merrill Lynch & Co, Inc. Global Pharmaceutical, Biotechnology and Medical Device Conference in New York, New York. The diobex presentation will take place on Wednesday, Feb. 6 at 10:20 a.m. at the Grand Hyatt Hotel in the Broadway room. About DiObex DiObex, Inc. is a priv...

DiObex Inc. to Present at BIO Mid-America Venture Forum

...y, September 26th at 1:30 p.m. at the Hyatt Regency Hotel in Room A. About diobex DiObex, Inc. is a San Francisco-based biotechnology company founded to develop novel products for the treatment of metabolic diseases. diobex has two product candidates in Phase 2 clinical development. DIO-901 (very l...